Search research articles
Contact Us
Filters
Showing results (11-20 of 17) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 17 results.
Neurologia (Barcelona, Spain)
|
February 21, 2015
Cultural adaptation and validation of a peninsular Spanish version of the MSTCQ<sup>©</sup> (Multiple Sclerosis Treatment Concerns Questionnaire)
E Muntéis Olivas, G Navarro Mascarell, J Meca Lallana, et al.
Multiple Sclerosis and Related Disorders
|
May 25, 2023
Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort
A M López-Real, I Gonzalez, D M Solar, et al.
Epilepsy Research
|
February 23, 2021
Perampanel effectiveness and safety as early add-on treatment for focal-onset seizures: PEREAGAL study
X Rodríguez-Osorio, T Lema-Facal, E Rubio-Nazábal, et al.
Neurologia
|
October 29, 2021
Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter
A Pato Pato, E Costa Arpín, A Rodríguez Regal, et al.
Revista Espanola De Enfermedades Digestivas
|
November 1, 1995
[Comparative study of the efficacy and tolerance of 2 types of colon cleansing]
J Fernández Seara, P Pascual Rubín, M A Pato Rodríguez, et al.
Plos One
|
October 13, 2021
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
J E Meca-Lallana, C Oreja-Guevara, D Muñoz, et al.
Revista De Neurologia
|
September 24, 2016
[Fingolimod: effectiveness and safety in routine clinical practice. An observational, retrospective, multi-centre study in Galicia]
A Pato-Pato, L Midaglia, E Costa-Arpin, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 17) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 17 results.
Neurologia (Barcelona, Spain)
|
February 21, 2015
Cultural adaptation and validation of a peninsular Spanish version of the MSTCQ<sup>©</sup> (Multiple Sclerosis Treatment Concerns Questionnaire)
E Muntéis Olivas, G Navarro Mascarell, J Meca Lallana, et al.
Multiple Sclerosis and Related Disorders
|
May 25, 2023
Alemtuzumab treatment in real clinical practice: Experience in a multicenter cohort
A M López-Real, I Gonzalez, D M Solar, et al.
Epilepsy Research
|
February 23, 2021
Perampanel effectiveness and safety as early add-on treatment for focal-onset seizures: PEREAGAL study
X Rodríguez-Osorio, T Lema-Facal, E Rubio-Nazábal, et al.
Neurologia
|
October 29, 2021
Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the "no evidence of disease activity" parameter
A Pato Pato, E Costa Arpín, A Rodríguez Regal, et al.
Revista Espanola De Enfermedades Digestivas
|
November 1, 1995
[Comparative study of the efficacy and tolerance of 2 types of colon cleansing]
J Fernández Seara, P Pascual Rubín, M A Pato Rodríguez, et al.
Plos One
|
October 13, 2021
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
J E Meca-Lallana, C Oreja-Guevara, D Muñoz, et al.
Revista De Neurologia
|
September 24, 2016
[Fingolimod: effectiveness and safety in routine clinical practice. An observational, retrospective, multi-centre study in Galicia]
A Pato-Pato, L Midaglia, E Costa-Arpin, et al.
Page
of 2